{_hϣ@dH@jX3.:mu!KL/T6,u{i3UA68߼v,ϱFbkM};w:5{z#~lU*vg*~VUsl[Vujnu-;hl[s6IkξLEs[L?;83ʶexCNP{;.5GZz- 𿴽uN~.+S-{lrݽ<:]'ҽ\?N-dRoL&-k%Nw sOGFlo#y|2:|aOQ-ld<Ŋh)G7[|y䍔)xck;xgyݛ7RcP7$ɿS~k䭞ZѰe?DRQ.>OOƒ$#m^lm^iA$羯w2 Z~0P/nYw(*W3l3g%ݳ-Lߎ 4_^rzB/\oo Igd0{!G?銢^ڧg+Z JOӤqi/:YN ^]Nn+­~|xuk_:_wl_^pcm?iZ'#o7,_]߻?$FF:p`O)37w]özA>9cI7c?W2HXl_GΥ<)XGr,KP;#*^|RY+@TnN9.l?rá<5>D)Osʡ߼iOwOs ߔ-iFWǧc#0}S_`ɽA<|,|͏ɄP ofiq/4᭾8%׏U:=+3}P-pj-m4oӷ s'N#)'z?rM3Z7 ދJ~q'gmQ|ar髜?se[]{JpQ{w|yo+kIEQ E.8P/{|Tvn'd𥞬x?G"r"fɵ/ z~)ɋ+-?R]W~Pm'D"N]:/5۹>OGc{qGað{苛󟰟gDkg{c[Xm"9>'u{{'guF֚]gؿL[cAU+*r<|g9ʩGJ2:uo 3~vwvU83P5\_ޫkG'k|q;Q {t|.`oϓG`dWWHgܶ}x./:{в/o_xxܡe_wvu/:]>po(ןsW{ 6`J'G~AbOQœ0v >W?tG{_Op;8Keݿq|'mHԓߋ'#UMOdA?\;WGsMVzO=ZgO^_WN tp:.mw] y[msL}{=׹'kOtKzTՉb:щ_F_ ըkWѺ8? n}?͘^Xۅ^z6)9tdXF?ipxعZaWOViLks߇๵ǛS\N&OEl\>e ~ziK؞Fl$ǧ~,GM83Et0{;->iムK [oÇw.ڻwvghk9o6?fܚ]?\u'0~Ӗ_OO asBWr&4j$8Γנ?O_o?t6&?]5Nju^*ןW{u<`9gG ezqZ48@ xpNt_m?{LݚGPߤKnP[W b?O:4󉿯\O?1L;9_x(;ǻȓo?zGrzv[KZ帆jX-1Cd>yɓ&?eoB'>Tly84N00n0B.LCgMh/,?WOɾ>[L[E#cxl|P7٠yJX98==_=xf$;Vԙ GĿuٓGP[N[_>ߴc򿉥׉}ipmqݩ~O'WJ8|z|Ӥ:8e3metfc{! 9m G=p۽odro7~N&`G??L<4v^cW Г]? ӳYOʕ{Fet:˂<󢳏 :i14>)޿ܕ]yLӃqb29Y6?l+?͵x9>W3Òv1>^ϬI+=̾\_Ǖg{z[phxz~/Ó7.GOSiʸ)(`M>nvxhQغ|z8tLÃxO?f+s!fO=ο^)ExIp6LԨ2/&GƸV籓&mdgf>xUqcQl9I9yē§>ǥaƍIX\щuzh vIlc˸br\*t7&zbxb\h?v/z^~)Ę{ܚ6<9ܶz2`x:-[5%d_|)?D3t>:Ҷb"fkyK[OQ+I2aY&/5~u%ic.~x?VP|3YWANVތ[16ͻ㸎ӛo闯>l-p|]uRɻ>l?m|yw%o\Y|Ƶoݼo OA_4_<4ۯO?iF3w?ɉt7_ˠ[2wi$~{W? $ZnwNvɩduj?yaTpyGQɶ"{,4qM3KNFNjv;G Z+gq`~}ef54_}%iPæ-=զ!}ί=T$]V/>Dzw5Mۇg̾wzq_v;-wm[a^bzcę~;;On-،k}*7otjrߓ uӓ9jKMOg *AF~dz縕d\oƒ&m(/2''u:{q|+ʤ汽rx@ihv5~_b.U~ٴ 8 &W˷y:wir?9t=45,<xh^lCm_;ǴcZ9nf2=J/0g龎W=:U~Jt[H$'i{|8øO>m7\OxB̰gmZg:xkҟ/O.ε=a=;3_Eml4n6j4h{`LՇ9qn:s L ^x}uzobƗ'ǃ/0?iO9mMN^/U4N&,"?_qbpѿ1Y|\Gwq⿅dw?R?X2<$x_(\<۽ȏGe.&5IIvi:)N 7́E_ 6/{npwpv7o62qIn?b 9~<.WgZX>3emq|Oneg{C;(Dmxv#yx|1J]]o%ro J|1\ϴ.>ϝo/;kGvB]*N^yCYe.'Me2wݩuKqs+q|<w˃^y^κ{ڷs<\i] q]\U6ڕA{|[hlOלT`zֵfPR睂{pN Þ}u+V* o/蓪#y*p/*Ƨ-R]QOgKZYVbEԗsk> ydl9vQl=LΕ:?定_>fݳQ?_쯽?-\M|~v)fޱWR)6.<;.ivjױZ"Q<Ȩgno6ow6n RUϲW[qwŋo/?,|vKljv{`][ji^Jcpd/γJOoۍ7۞جfWV}qh(oOvrԹݻ,UFp^i o_85 sԽQr7 ^dI,ծLk 󋻍o/S‹XP^X9;(ۧ}\+XM/r޶r]沅ԮsQ+A=uVxj%}'1iPǸ=U:ڠ2Jެ]߷]˶rq/2w_o/7rz)wgkʗ]+wÞnK7ǥ~AQbxQ:7ߊ_>jW_r| uvlnwGJmSmЬ`?9n;.f7ٗĶv}>흺6^)oX=.8T[+]֙}vֶ_t޻^Ώ_2-s evq[?`3'mΏܜ-&3#м(tFFa)JNXw.-SZj_gVu5;qoZq|nz{|>kۻ0ں;{QΝFe9/ϜW2k盩OwǾ2χ{ȸM~:# H2Ķ]KϾg~aAVՎO/ ~J\ovmsB<ߟxslSmxw{V_(M"Wv]Uɦ[W.sy}˫~joPfKZp$uJo[GG_\>e[m9>s~Taso;̦NRi'?=vt63J<7Zhb4RsgwݩP.j66/Jg[gS|{_.݃QNou(K_>oTp+k7wZK]SԚtӧұ޽8[>jUK`k?~xv>^*_ޜ)W•rzzsM4ʵ\ihvt?R;+ǟ^>m}LE\p=|xY~t}v_ToXt޼IlG )RacV|sv{{-9\Yi^ܛй\ᄐh[o/ًy\Y+]fNny˿7Ӿmڣ㏟snn ݹr߻LZƵѴ`QˌrVMFl?r}HY6\/vM{ł|hgӖ8es{ّׅ5t{v;r&];{~at۽}Vz;>n6M6:ko.sVvQ۾ΞR;+?;bRWtYwNjg/5J{֕SK%?RZiͩ Wg⦺g^m?MÖɥ>mׅAxƱ;nQdK/Υ]`P;s٭doA}q.s۝̛/c_,}=>5oհpZ*_Fh]KS]̼xq6:IZa\\A'[cq:~NѼ{ocGJu&υF~]VQJ(]5m4]nO??_:OsvM-t͖*lv/~ܦT1j~ّt}Tlגd,_},_r~~ 9wgo&_J_W4%є>*ͽVSlk~R<ԷGp=znޝ=}^Լ:pIƛGѩvpռN^lo,|VӲ6QMčఘ*wgOË~ŕwV8-$p !bRžA(]M]w>Ķt6JE`(ފ㳭 C&+Zl=+GoپH׏{c˵Vrg@((/;Ծ7ūAy~v\s뷛ʛg/AcΆqWP!^$LIfb8=ԧUvaͿAWǓB7.ǽ1=+`#&@KFAa: 13`0!Гf]O2O Iiø|}_ߍ &m:`\|r<.66uvǏgtm0 F0fDMO?dݏ{?X[\qLJϵ| j>?s?twp:~PAX,̤2<}tj(\0Ό뜉g scKM xiCם׉_hG||2 fVLnDM|Bs3LnY_$ZA2sy6;^A kS[ڇ1Ҥ&k3aXq;dcW< Í9]q_#}Q0$[zpUټa%wW3= 8o+#5?i"^xK}*hgrz'ؙD܇3aö8?8=9m;6H-}i[?|ubg_~~/u&N_?~!sm86\ȵg$ǡ)#q?y¿>3/+LNgT{XsϚMiKU{{4E/ǷO[o'W<\ ]|ɕkz*rg^n7  {쟁Iǭr:~P2>0xSvHw–Ĩ%3}xh2 L{~?Afʝ:?)s)?vZEM& O2Z6f{fMŹ Lh\<8֦Q>?$Hn[ӂ$5A<7$qMt6Wayf")Xgs'~Ny4r||taϋ2?GdO{;x8\V;ǯ艙O̩Oh[y-{r6w57clHΓQatz{x m&y8x|xʊSƧ|f|0]\gPʺ}6̇c!Ӎ֧ibSJzxy 3xAm7t/׉?-93f}s箙BCDϦ1YMwdÑ,J'vVS|l䟚+r_̠aRx?E?7;? ;otz?!M?ךj}a?$-d& Ǔ'X|_=`wU[9&AU]n9~799yC1hR Ň7n3oWk?(Xst yY{H=vw6<0v^Sǟf^RiǗOoMݨ/ͫ?Kon?GJ<n[_j!K2xzsstH?^%],$o//_/\WhO.7®IW{zL/u_G >(xGs?x+goU*?nF.?T"3x{Z?nzw[W7GzԿbO쬯 T!Q{zNCo jWhٖy_ڥzG1&wl'6lNѵf5kfQI郗8lYL.f'2"5b̖'%,R?yr,z*u\(ic4+jZU-u%q#t%eJ1ӳ\*H/^CJRZQu^^wfğg`% le0[zYXnD1n9G^"XM,г iFV7ҍ[.='cɪjܰN&gkNq-;>(A~30{SWt* *Rwbq, K' DT)UJX<reVh!Ѯ-?Ur ,FV1w-QvJ7{tiQxH\77W)#w/'ǟ>{q3 DsdXD'Z閗d--'C/Ņ@;Diąb*F@9'BV"L>J)Q$@X"i9?.! X +bx_/SsJVOS .zad3rb2jB,I&?V,H-XXhJi! L7-/VAj ,|t6/Kj^,Q!(WfZ7rrMO+:%2;$%33dsi[V6TJwZi~4@tUEWUH [6 =ZI3TQdEjrR)-"+ctei s2 (ɴѰLLrc7B4 )r7`X00ok-WUn d3r(,\ʊb!H1"a:7DhD -45;;Mxf"A~IT?8N1TvI.$l^s܎0{۔n T^K݇LrbqamA'B/ѰVdXVҽ" k_!ɒF?D ҖV-j!P @ 憾Eaj*^jiϩy̾ Xjš$Rm(H+SB@%݁Х|ƫ2bb[[qG%/0[ljZyѰG4(cZ (o@V3-J\Aْrn[lmŭT՞kHyFca4KG4'װJk7L/My:M`Eu5DOko 1 `%ZM;9'Aʋ¸D!Grjz'IU JY KH^ &|4\l5w5*A Aͷ+v4GdEjrRY㯉DclZ\FJ|UkSQ,(Ѷo~1Es)D[\ geh W _1I#@:GRzY b1vb@,eeRZ\짺kCJMu2"hFs!fqa~)/ ;YY2I zEꃚ\TAN ^ bWK{NMͫfYE1>֛ooۺJY +s!{Mp:vFךT9-.%J=[=6H G׺J(6?켷QjnM1 {!c>:DifK/Eω̯~d|_R7x_>S M!ڐSUjsڊzoiMלJ[EIkU@8eɜdŦ0f@1 nmXۡc٠ߵn;F=)TTqRhEpaʺa80%Śr@+_ s)q@F#bV6?j8+E%uDž|JApBW t麺MxKm`il-\Sŷta#c"}ى/@Ť>ֵF^-Ujh'#?nу 0$xaɩŘ` lHV3"dzҺ~9=UvaGp1.Dh_+if^zi8 'U$.ϋ Ah}A,0h@^OlIT*-x d QX5 @>-e{F(_uDЍd;ߛ| %|I%Ůtcuz Vt?p6\|l!k!vD#j紃G KWRR?yV3Ufs^VzztCcC@4 z A xɜG0 \kHAMXHr"ma,^ibw1rtT%*=bWK{NMͫfE/OiY&\k-1ITnGӊ\Υ:h@HI QĔP ldt0p.DeNI@+@L(20;ng=.7ӺٚS"5!6&?z0-`V[/ӏcL&.eM3yO²(̯ua=PLU ҆$':7jūRJX zhy.uݷzY覤 Hd l" Ridxs:cлrQ,"g}6'VzT*RDyaVzwg`$U^73Hfgh+F8(d+ى{N3W7Runu 1p:Sh5:iE{*DkBVr/9L/՘1+Eꃚ\TAʉBsV)5, _a.D5\]$=XWVt!kB,SA:cW겐(kWUbsi,f.^+9)檙'me&@$+,C@+Me$tGp W' =CE kHcvYqjs X ٱj6am4An.k^lϴZBbPHf*1NvF*LNJ(b {mĂ1 V$&ى'VzT*RLxfC偐x MIlM4ṕ3Xh B0H@jj;kj*jnb̦xns')%%IݶkY@ѭ"k< 2FZoT:m\A~R@oltSQ1z @PB63k4 pf9SJ bd&ulezY *"q/Xdc'xzo;# @\ V̸{͉qABv˟ߎ~m+30"猸:,ʥJ+W+ɇQ8$/ ܈XTnڍn NT2Xx Ck:aI&X ݆io2lj# LI8-grf=]'@vX #`%5YL.f&Zf ,1l{2KȪ+yQJH"  ]=||HlZIm1 "cZTnڍn ?[O ! !meӋVKH }cr_ č1p:ShWfe't~8vZ],eEmny fݒGQ<һ SjFCXFgXͤ3M8i@"Vc-uCKj|tTV+l/vN@"4X0ij^:ռ(ƇEmb 5G/_S2fYnT,TtaM֜0A"Y (if^zB.-.MeD!K&vdYq\{{NlL`U~[$?p*µCנߵn;F=)TTa-:vFךTՄ" $F cD'q]J ̞ݴJ}k9f&اE'u9nhtX `&띜Ō[l/H1 `ܸ-\!X Qԭ 0NjWo󽎕US"(@lw)*.4VC1 "N"hh˶RiGgF-$f>*eޙ}ĕbEV8 7ءk/ DhD p-7lQB4=!h&6C c!Iu\ױR4@JV3[mr@@ȍMdEjrR\^jə?]qB/κZZ5D$"iql^]f)w{9k'/IUxzMpzɎ dqawqWZLwNoB&V7<9-[lekril-AN Yr*B7guszsmX]]vfD!QtRSVFGdJ *!?%+UŸUj7 =;Mpܭp&G0wiJiMnT;%i[rMYZ ++2"h5'p?mz%LE, k3dt=2< |`UkWClGmk Imifw}wN=-rYo^H4i[3؟T!V F.MSWT6I,yX+K|8c󿖖ɉgG b!{(d3ryJa@gˇ]`oI`E;uF@ёh9\Ž)yZZHjNcaѽâLA p$ə@%d6U 2"5b~1"-ZjXC rjVmvf.Hnv#0Ɛ5Y$ybIֿm(XzYWG.#¤{%' ILAZhH/uI%)KA-朑=K$DA`XFU-Hȩ呈DvV{K'O~6yMɕŜyS+4Dr{@ @rbDly9p~jE!XgEm< ZXl?% [>*.]*+ V"XxceѮ'GHm8 h׷ҦYG:Զ6V2X ia,a?A]bqJhZ:޳*:AސąLE=^ V,-H*} BC04R(|%g jAka6Ur"k|@)NC \lVC`'OJNds @JLg+)@Z9jV)?[zsyf\(yb5k%^WxI3, "㡁 BZR72913eyC/y#B,1hwjjèTMAHAMX Pjiϩy̾ KQ#T@vZe!XR&s%ed <3v Y5!g&VMp=d(@$Aِ3!๫:Rv#OU`\[NڐAxm)iI7V:* fa(ϯQSfT;5DTj IV9) h?R2ٮb b!ѽm7WdB.v)Vv;ߦwW7.b]l$0\"c3=yMZO \k֩3֬rͬ&3. b!J\ߪ&띜Ō ˲X (`%wA~=U]+]н>wO_Rpjkp;;)dET$Q)<3GN+^UszSi굛v!6y ;BKoz|5YRr;r:3t!]oWr.(}m cRYQ(if^z,EAC}Bٖ@*`n#DBYΈB8mٕYM, L@APCk: cLBxVcD%, dr5-7_o f@irR`eZJ p zfrڍ']7亮[ѓߔjiP츝q lHqf_3ɲ)@$B4=St9xgg{!afYjzg?gI ȋѴ[b,YVUd_I>U`5%zZf$TQ$i:ibǽ&띜ŌU@來R:M4^Q!Sy&A@MH0cVtoQ=m9F|{< z6Ckؓ& DT9gŦҞSS󪡙}ANF)DQ\Mˍ׃]X`H9~YmiS+݊"@ BV>[үn#@ZyKvx@ lvEqZB %ЫC7VUkj7)"]XbJU|մ5@ŧՙDu]5A+K!$z7~Rn˥~Er:vFךT9fe'iE$K&X;BKp=lU(@UthAaQ>K*sBMp'yAXû3ndƶeSk=zZi8ZSrzɳVsKmh!6=Zsjj^54/(,NIŅI޴(tL= 5s5(6@kh&tU*{mol>JFq^Wř V$ _CI6ѽӚ 1ac'B;iT}d3 Bѳɐ#qfkBkat:H*䮜*iYϦŅGfXhᚩnf,"%j)jy riZZ$uIUk*~ +%@R+0="hP >As?@l)۸NoH tZ@$":J Ŏ`\=[$F@ \"mE·@Ȃl BVZjGV*fmϊ;k[-Gely#.QB6d*#Dubbd(JԩFE66(T䊥 ry>,e$JX@f'cXNC,p-TfCwԈK:<9 j*X@ئ9F&)EK/v{Լjhf߿1;LO%i@Ȯw`]6n8@qtqt]K\a5d_XEM;9'A)⫸e6R=9A_.ƴ<f~P"˩\%Ax]Qj [ѳC zө-4)m% Tt@qBSmgtYMYM՜(̴1#[B\Ք7rb<4X/K=AΦΕT/jFS~k;;qCk:~qp\@D(z$Yٔ29RD};h+n^C7x|yj/m 4ؐ`?ѷєv=wf҂.tV;{xJ֫Ta&:A!pkr^˖oLVT(WQWD'mS*]7nE`H XMFnR)˰UL"(j孥pZ]Bp{okTZ^\VRs_kKSQ+Wә+1]Wć?~9>֩3֬rͬ&H z \AFQ&W,Us~@lqlkǐpjR'wK)f d%eR=Qdaa̠OkhڵADiFYQd}^ tx/z'gv1#JS! h`ᢡYI3둲_/:vZ|o rIt)!{X@r5[fGsvUՊ Qt"a%'Q\o^_8mhc*Xipa"DS[ia{L%V3WgL<Qm"0nW O}ta;:DS Cf*@m ^y#ՓA[ʍz-[q3zۣ#K3x#=%+U XgձMC'N0n7wkD DOF3P%aq0^z<;X@T n{bD0= hJ-@tMo{R6ݹy!ae{rl 5\ƅ{{C zf DhAG!B@>`5Nѵf5kf5AV0(T䊥 rNZΡ`KƢ\d~/2 O 1^b!vǼF GN8@,̀)(UŌvEn;UFWHnO5ˊG2d?ӈ kzY r>/.t$ "h; \dG b[`5wjUoǛz<=^Zhftu/'j[r "ݴnXUpan @7yLm8?`;qAQf:%kb._өxIt zHl9~1bWK{NMͫf [bf5YL.fLE"TT]kVSfV̴* @k;:d],~hJi-"*[PjZ-ov&}+ ^eP圊zZ?'˅YmsUv{;ؐB4BdEa@IbaT93>Y(}x~k]{^-UrٳMtӓ.~Yl9^vnzv,ty/ݗъzGoyKJ( "V8jEMF'eWDWAΊV 0R<;JXI2mjHzRUDfa<3 X4DP bWK{NMͫftJ Y;0 {mUⱘiY'A*!B^Ř%@؄z}PANs:+?ią5+RR6 z7(ƇAo}z@EVBK+x'2WDWM;9'̳[@DZ bF5%`%Fj4:-: X"ayV5yW˖XC"YğB WFiR͊?@ȝ5ד: &HŘ& \JO("# A Eꃚ\qZ~#0Koia&% 3Kr0,3ZZ5ڸ0!8:zeY+b+cHXĠ4nmwaFF\ mmſu;sVYwkqU-e~'+ZL@1 hwiޙ2Nߑvђfex缋BKCs3F߇^-95568@%UKVnq>@h+jAFULV:]ܴdjeY9!9k1;cj-B9}kH(DaֈZLN/Da),5{mU,_Nu{ Tߎn-njX1P$JXY EݫPpE X)p߽7UF/g_~ݾn.nߒbň{M׽eӯTVB*|C;rJ2% PDG^^,i 4vDFzOxջV:77!py吷Wި+xtjF~AI00K/S^,dMtIqZ˒BBzFi ("ޝx3MI:0.([wIV o0୵O7wM]mBmLE{:vݔ߱=x``ۤo7ow>y`O60ųY vSgxU5Tѵx ~nJpm`+j:@n<$BD`, |;Nl+l4ZmEX.oǍڢ4tٷ[>ik6"J9Ƈ@n/d1 pESX7G6`WZl< BO(||sq/֫4.>>[.T*'r|0"RCOug5 @e:>)9瀼GwGol#=.l aP97~R?_tnZcR{Q0D@%rA6;a%WroBO[ vqKiӹH@Ftˋ(˗b}<\̒y|0Nd"-U,E籦B+YOJu ur6ZY%NbV/';A= 96upZy< Ep87Ȫs/z9o{O0O-fI#K'^g%WAՔ,PDAo&[<: o%MLkQoDl6Z@Kd$ `q4WV4Z011|RŮhܞrJNeBn~zYbQ"pە{bO 9G:/Ers;7NWW]w;ͮgAexe1Gٴ %HETuj:Kgӭx雲q|<7~R?_tFkz3 vpKv7id댢vW bhA*ك-jx7k7bC=28ot128#%rLz\ #+q%am4ڵDWOEV08*dkxHǤD|ݔni5yFPDEϟ?<~Wr'@ѽUxCtqGZaxpSJg޻ɃաK8 :x_BNuxZo KqxR,=H,x|7ݵ@Gr8R`r,@M6u3fjw֊Fog`ׯ8ʳrZٽw+N#>_aܟo@nu "a#f]b?WcA/]Pow%(Syz 8R<[fWjX]ue0Zi2N[IeF.= w??0: esOf^my~8[۝!T h7'i%mߟm:|VۢP-Gi]Y%r&,tzQ\f3 nkat h`, xsg2KNۏka9Z+m;jٯw.i O +| s1(w֋ pB˧Vw74Cy8|ݨ(= ZQ2Z6)]5*t|wArȗkk٧WZ- &xMn?u4௯W_K߿ZUه/?tP@anx7GeV AKsyW @] p(B_j&@EYehӟLwݶ 2șz7EAվn.JuvSƂܟC1|y~*Wujs(itJwaw7NWW]w;ͮg/\<{@nM)gP8Y:{dЛҨ. k=2zNc8]4Ywۅ@AQҿvh3ۋ\l}|?|oǸs$&d3^7h6vg;+- l#U櫫~|;׃VXvpsrvk_˥v* Fn|~ITjfqW8Ǜnr`WpX]kZ̳nh '^ 5,acղׂPza *v:9N3^6:gI+EkێgeW_66ۤ}\6wgnOj. w o31(P/H_cժ۾n.sT@>QPt\( _q*rIֺڈˤmGlz> :,]wWnIEUnѽT(tх{")U,8jKX7S_AЕQҿvͰA/R#Js mt6uP@f6B#7R5-^͢_u(z_n/d1 ȗ\gx\I~(שGlfN/ *rIֺڄ gץ/˟<ޖWYtL}Jd\}ٷWA;QP@iӹj_RY/-ӊ;IO@s12Ǜnr͠kA>f%`BޮKxgqlW./֭vneIRQҿvOnɕyvǂz_@] A74&zEB ;o%Զ^yaNV2a~x5놼]ʕm{X4qtwSy-Yju{\ _EZA_{!RN#ʿ-Gi]Iɠ O}_+k!w#=H Vt]U4QҿvrPH ZktZ 8?O?lhtܟѿP3}s:;iew7x .r6t}sm U->8)/>bh8`Oh?j,ӋIkxj.YppԨ/nEp_Pv< 7wșG1谞a{|i"YYAή+r߮kmz~R;Oj?$X_4z%7<:ӹGnK/_WqDd<ҏᤜ|5Z8-9(d;6u}H{7'*]5m㫯|_N*do\.Noz}w%~J ~UÒݼBG3CCSNL(Ysw@n$0oUM/͚Sș.ۃf=|Ql 8m6Z{mYق-@<ofO|Նf>{9n#tGn{;#v y%h:}q-jd&ڜLgOպkq8pz>xsI jҺ/gge;Ae:e4oWrv]LlS_ao9]갵w; C8[s [ *KBJ>-:?+ pOߚ oB(,]F՛$ a|׿~-&ap!Wlv?jDZֹ`8Y4tuFQr4U oNOUO"T1h<]=*ƣd?5cig PDw (T4[\yaƷ_?Kg_]˛ c(qFgӸ\Ynfj^.A+vܨ-I#OǛ}Y/dv=|VnB(g> e,brL kS1#fnl\Zя<=b{\/˫eQiGOʳ7nƫU*i}-vz}z/mϟom']NuH7 `@>JQc1^LZóUw1)1'pֺ˽(>YuQgkU8iӃ0d'jw/-7{r2* eMWt-O'xMn?uC:a)@=l q|ݼTr<{1,_d'&<iItzyaݍʐgZ v";XJ\Uǻbvq=}W?_}Ͽ拯rRٷzz:8(O'Gq;kE] CG% u$ \]}%]\ݞ-]Djh|^6M﷭`sz9Xfb~ЏvKa /[ E~((|;Nl@Thn  !O$ՆG2~Ȯ > 7"P:7kUW ,.|Y~W'rG|zU΢b] xK՛ S3Mh`\nc&:+Z+jmTٵ.Gf,@!iySy{[U {7>_pgFD7",Y2_xt7ҙ(K%5+4Tvh4}|*O'Gq;kEAw,Ž'AQ6 +v.4.W6񮵛^d[AFmHQ}:ۭzQzhI| A̒]eu闭vIpdTN!c(1u: 7m1oJ/S^-tijBޒG pc0x^ GO<[fW7vԐRI=cG |ivPD(xVƣd}ݮ]'E'hv#ɦcay+zu<ߺkq|!H\z. wNOxYhu2]i\ɪ GޣelMc*f:Z]7WW_K߿Z@!x\P_.I'%#m )DIbX^3R_TEH~ٵQ9ϲZ7\'VL,J*c?<)݈ +b"4TaX^Uf')'Gq;kE?v8y FO4tuFQr4ap^$brA:v画ePbyU]ԚhA*I_uY?,?dOit'o)=+vb?/:A_j$oޛIE$ wѫ|2FOS٧z& 2N( lXVp{S _7vLc( i}}vJ 0ooS 9{vU L فIA(d$O>b:\ùpv7id댢*hJ oץ/Y<[N,.`1ǃ,r]-T_}bױFR2oeul $'×j!gOTh՝W/hxTwGݨTj68_Ԗ{?ZH/[ J.h͈s"E8Rei}cW8@zϯEƻhvyp9\'~f0<)otxlz& ZժD_Re3wUmb5vv`-8`1_e< k]Br,zp8΃ۃd08lfݞ]#[!'%]pU?QP@oul=P@Y] {^ g7B) p0 b0х^␿4\ _o.eފ7w#cxt|% ģlS[`Ty2ExA*@]vr3a|ݯFojÛ Qurf5+ - 4'cMW|(d$vb?/:A{XdB _(_ kk!gNO 8ε|7ۏc?&ypi5fnl\ZQЬ1})!nE| ?̲4<9°|]2(RɅ, j#?զUmObO@4tuFQr40߼?!|ݻnv;j۵(GƗ$@ON!gz&|s,U SP@%ݒ(M"ZoZ~Hɪh%b'7x0~[*4z{|Qu@XCnJJ4˫$":ƣdNj; ˿/U՗//. _~hy? & B!oɨȸ.hZNxM0Kft*<;U9r P8:r9ӌ8R2WjN2mgt7>%(˗ ʲ8-:Φqy0yɱ@8[sq|M^?)oJ7J ȗ;pojo^(v]*Buzoj\VfGyV4g*NhI#K'^g%W?])b7IMi\d^^ 8;(`q4WV{9h0]K($}I]x̵s 4n!u _0[rW Óߔbgi2(/e@gxdxgq9]'+?Y,Q)ySPDɪ]4];#u oץ4\$g2!<Z?ߎ*vɩ24ZYUmة^lԾA%ƋUuQkv O!E,p$#I#K'^g%WAU E 8b G1|9xlx݌ٸڝUkd##ǵo۵~^# Ȟ0w% r,$ ǘ;2 8Re}][ި_K ٧.NS#vPDqOBP<1ÐA/]ЪuƒM-K{/}UtqMdWx4Qq4gj_u\ G"Q#]5vu(0%xI#K'^g%WA֕y. ^U՗//G1 Qp? Ghp 揄j(gNL"xzaU'/~7n <$ 3< %})ϸ)*W&>kt+*Ӈêrqg0;}W/mϟomQ:\nN:5;ț9 @&xMn?u4;S cKU\Mi$DڰSL٨}5ݍ֯ܺ'OW(@K/_Hx*?iQ|r2ƃlXEgӸDlno.Q= p$[r6Oy{Ɨ<.x,JJ5䯒ɾmMWIiHh0W0ٌ8Y+ ZOU/P|IF@~ު/7=z[1_b%u< P :U4Ѡ٘ pr4tuFQrݷ+Cޒ,~-sxVcAlfFMZ^޷5++F]Ov'(Y3PyӿynHy+Jri.Ƒx@;gS?)C@,O\l18RL VoeY?ھQ}ݮ]'E'-g+]e< QҿvZxx^eT[ݪqݔJ?Gj)^\ΓyY=N.n|!BSMl3M,y۵T_O1Roo/Is>Hs/sR*n&(ΉxTA̒\,.s}7__׫ydWŲ|6] .Q:WT:4L"-U4n.ٮ> ’2$d u @U&Y-z]}R>~˯ٗ|w~by?[@hG>ٌ8Y+ Zƛ#8C]'qlq6@񜖃}ݮ]'E'hv{ap/",?.NY9-< 䇫{ o6 Ogxqpd$QGtQr%TNlnNO;@*e]feo120 $L(om ߄8Jh5WCޮM__.o*x%(?a~q\*iO|{\I[QӍ <)ۥO3[no۵~y ca(qFgӸ\Ynfj^.ǹ(qh$>ofOlOZ"w|Rr9?|7dЉ@_PvEk38;w+8JWY 8tAޒQ98<۪7Iqz\ ׳OQҿvރ͵5pk!|3nJ/S^ͣY2(M\$qh$X1!Hvrru6-eoҿ>]ϢEP d7[/4ZP@?N۟JQͦҋv,WlfKȝy.ENjrZD|&gaip-CKƷCB f4.y=YI1[ qK>7~R?_tVڇ*6vzq7N;^xKB3u 7ސ٧x݌ٸڝm〢`ϧz& Z޻οޭ~T0{ܐ7ܐٰ%NOjipP@ׇE]_Y|dW, _1fO!g7[Nw&Ys8Oռ9>,}ePo4?junCJy2E:[-&ݓلÿ<ݽKǝph2JAh% P@A޴O'H8TbyU]Ԛ|Z~8.țë]Gzy|Ѓm;llkI| zj 9{x1u:?)9|д7n.Q{1ntgeqv֐ʫM|^Oi|K]5j͒V|~9-<Ŕ{H.Fpz1i V:{l7%C^i?B]WB_:L ^%G {r]%8MV7_Γ|OφvQ]t]+с|]Wv}u>n_nN_U|g[>E٭u/ٴo>$#KVf]OOa(8ε9٧o-a0^:0|Q4:awQ]4d3^7h6vg9nڐkMW[K֛5Ͳ+ OJeߐ7}h3ѐV-]l"OJec o.yw?Oյ颐=Jf{bx}^L ,6ڱ<@Ty 'xMn?uӟ#~]~VNVh8K"8hHi#) <{kY7 +{r)#~-lNx׫8y0ٌ8Y+ ZjhPDj R2/aw:-'Uן?7~&,tzQ\N-<{6{'>UWKe@ @܆٪52;șy?Y?XV.(uxQ9J(+<.]>BڠiaMkgt~R*(}(bFjˆ(M 4d$sTn3clfNr [jo\\?jN*W(.vo|ܨRU.Wl1Hd2ȗ GVqT_|ݾn.4{a|ry >pwܞfSGc @VV7x PHqcx~fYF`_ ٵrA}7T;)T}yBOO<]cY5ZUΦͨ[jU1m(;i|p,(x4Ei]Ihd8A^) 3e8@ k Qmv-zN TGq}Wo٦>ٷ6ݫ%p~,]?4x4MFU-@]kPLwKv7id댢*huao۵~υ xQҿv?|?x't|"8v_E$Y gɼNGMAnQ2|;Nlpr3Vmr!rv]ގE#iDxo6E}~GX=|!^BOjǺ<Un/d1 x.IպCSǗ.4i7j9ײa\/j罸q(# {5gPO+(/g_~ݾn.ZG7{kᦶ˸ :-O~~3hua04E#uQ: 𤔌 xdQkw6+@t1up1 J.hu[>PD7/-o?_\LYMY<[N,Qܕ{ݤN3mn' û|% %jfWˤ.Pp6eZۮfM}\/@Hץ1e}эow8rM2u"R5΢q,8b (f K9@!UtlI6> !|}CA\VxJ`xG (^ Q A[9؍%e=yk.rzP r7Ű ZPyo/"T _qcx~fYF`_$U4^-UUaXDFouOj&wV;/?n o?{npS1tUkǃ(-Fٛuˠϓ*, G[vVtQ :QK8@ԩ{uA~%waI)|YYrvhhʨq;gY<(QҿvA q1.a0lfݾڡCW]UNty>i]f":@>|zUBoH:~h S 3ŃI|ciP@iS!g?NJV\n |% yY4Nn;eT8鍓Eo뒬h[L 8,@nv{Q!u$ (7cƋE9lM˃h:EK7Mwwût:}q)%rPY f{zjͅ%>bP," s=8wΛ8sPЮUCW<=5trOEnIEɕ2x?T glkI|ѹs'voR/ xHE Ys$cj08ƇJFb%HV8 *q.]t}VH#^@=._\vp=vЉnMfQP@ײ hHh0aSf}9ZpY=M`GѮ r_:U=l!8ub<.giPݵ{UwFxR];,Wfz/Z礤o@`d]zV>(to>Yad@! ,RA@&{fwomƿ?F4(";'ȼ5ѯsxߵL1~&xMn?uþPOU @nJ?ό *zzLgZ_h 7!JTMVWɸuv>퓤~wRto{r޷MlMo(͒hZqTpB@8[z'/I'@A,i\En5t1kaT+a8+7Why< Ӻy*>@ U3zx@G7ԴGHd$r]d3^7h6vg(h׫ '`MW~|to&s#+W&;AQҿvA q1.a'j;\TW݋}^ F9Zj!/U՗//((| UF|\M р|I%Ei]zOު` !r0A^_hPHޫX,< IT,v4\Ⱦ(S-8ˁn]x*h-Fd]UK2Wpt pg<>(ϟ@|zQYZ 6ыx݌ٸڝlcuq[] W@p,Gty1O GPک)p4dP@2j~*zm5wf7OnIEUЪwÇITZ-h-hOdi0ZY.@qbp1\۫ECR!l~9쪼 4Zq4(MBD×(o z3|!Pqk ^qxq&AH{ʕAkvIf-+]o5E+h0/޾ĒBn›TOIs?bOiӃn^#} xQ9x8p9{yST&׻0x렧8v:恜>l[7z6ܔf,#=X]d5-xx @'C, _7OZx4#UillkI|ѹ]5B>Q\ Px&t=VoVqF2 .jykS?_V-|I2{M7.GI5~Q~ٷ/ٟ??|7斵Eq9(󯻡?mݤN3ۭvv]8HH9)U|^G| _ûn(r@YUyA/:fXzoÒ/|Ò%=wKFX(x]yՋ|6 Ö09AB _D7axR*Q98|kҐOz\= n|0]c(w&aSíM|SD`\mt6oqhnP _BPofO ۽͑S H7BP;~ÑJk 5T9.ޚ$@vSIZy4^ꋋYw637eyy6kGab=mN'_l! |E|eq pL&@8[9^\zݔF Kjۉvٺ?.AXU.|Y%$oi2EZ*e(ϵ?,I=tO}on;l !{!LQj qvk7nJ?5q8-x\WrИ 0"f.OĘ]Tˆ=ϩaۑVk * w @|:ٌ8Y+iEHJ}[7[X P@A _tQ- r9Nv,rݞ/Y{zqy޺2jy%ǐ^ۯP W_M~~3hjaS* $<6ϐy4xf]ONnu]^,r ,.GvI4>2YdJQ[4FT7vk^'ivՕy;x[{'Tܽ_k^"nNzmP즳nN_U|g[>ysڴOzMQH&@1*Gx\WWβ-NI%ku+jfrZ֧?-kux0kE9w՚7i{vcGt*3gy5/ww-ər oo~31 T}zЦ酮3̚~t tA5[@zQ |njԚ%rp5ZY-(]\ݞ-]Djh[{k\6M﷭`rv &G 'FwapPlnB oץU4xz&߼}NrMVu{۵:ߍr =sXD`\mt6x*l4Zm˅s|vܨ-I#OǛ}Y/ڮvs^NJ<n\2Ks|ݿ֫vSzW6Q?Lߖxa9o4ݱ|p PL~mr9odU{> ,m!gp%,N4l*@<7zrQҿv]p|*0vzQMY::(}d(R9gM܏\lhmIxx1 8)a]{N (h~ԶmqvYKdzjk6tSҤ(Um{1wS4$1KflWŸ9[eO8n/g_~݃&Z NE,/}kY{|9(-xx>yn=<)U.G`5l x\rX#2*NWhlkI| ڝfxuַ,"Ax\VM+W+u:ofObW _OJ 5@x)n/d1xܶSs]*ߔ~*J*)d5,acղTΫ޶UI(#_P8zHh{>R\9ky{\QrOHP_4gY+N|kRvb?/:A ݂)>N"y+Ax\ץr2WL _w0lfj P@_@<+Շkn- C w"r2/ۍpd$G8V4tuFQrF!|{ųevuO1O XtkφjiEq2h5:a?WPo4OU ~#EwۍFv/T OB%YW@σTv(_ kݭkb s1'[@䮒h5(S!Z={!x\f]ON6ox&xMn?uy}߼ޯln_|\\֙ch"z*# (àMY::(w }ϯ??bSw??X5܏{*@1'MjWzgo/'[wx?oC*٨fjw.BOgMvPlG:!˯_~ ɪNJd$Qgb8p ]":+g_ܶ=>J$ [=gܶvۙ@ qQ7Y"KN=*ŒJyq(p]g[0Z2Y w;sg4\?g22W;4ūq+^bAUiPMԧOOGJΗ\(﹡1$q<E]efw:* ,(`#ezDhE }:EjN@{l1|CJ;'I*ݕO'HnW*3@OH?m-'1յUΨ[ɹ]CHw  tò+,NSK|jNM 0HH_jm]w3u7UTDg]M aU\jhiGIZh!Bsa&?QqBeZv@ '#}-\ݠ' ۇZ_Ic4qXӨZqU <qQFA5'8K'2lr}[a@Zm J@K2<[^g0.d϶ϟz(eT7eNy{Y^B77yX[D M΢f~o3tۛȖIcE,z3;nhJ,д>mDW hNd%@ѩpA}: ۍ(Gȟ>1oҟ4_;uSc5L;Ÿ{2,FIf՛43ʦ@'Zhk9>fƸpךJ7 %~Lb ̗8V+oQ5lG.kzaf`LֱMaddgdgpTuH$#x,W0i hSnǾQݔQ^d\X!m8^ͣZt]js211W_3.3AjGcT@ $(@dQ:mNtnpf@M{[K(J0 NQ⢌Ƴ@ݽ"\AE :j R;\0Olg<ѝF^=;@/fi,yfҟ4 ѡK;ϙ IJȞJ:-8iY̫SNI2tanN @v,]3U@: uFhѯU:n]M-wi< ]<\@ Q-ga'(]fv.*(q)Kwh>VE:4k ' R25 MT겉XeQN <<7a"1}(^'fNer9ZI2=C@Nxɞvܴ~ĕ! NQ<'UDf*8S7Y%d%lk9>fƸpӵ*R+D K|0xFgc@m<|w. -dJh}Zgf]fnύt$ rfMșh5qRrF ZPhJF8*idW[ws? -TMW5V{Rh(i} %?Ǿѥ;*{5d/̈^o7FN~ .|& 9l=zd㴷MR]tiYvn's2W#\@ӵޓAL+ fIכفp K Z9ƀt̛%}*İ5qog"OjiNk,>G8}rCvu]LGLԄWo퇯>gp @LsC} %~Lb ڙ/gq\VޢHdC /)vd *-%ZѼN NKF@Mr 7n-֖$rKB˂rb۵;+y÷bBD ,GvQT7 M" ׀@dFh|Klѵƪz֙Ys ŚOhz`S/ i:)a"{B2i(%]of5@+%gh!4> Q$;f8vh.Ll-'p Sgݵ֩9d 8:mbM+ H$;4g)<6Iuq9ǝLrl'#L =>n>}m7;uF<ҺkC .R# ,m`B<H7i Kcb%$<0trd{}<4WU$@!,?ap0պwJC h@ pidak_3.3Ak$3EH㍳eXQ0Kk 96:=qMCh!Ʋl?=D0Qݔ9SL NZ^=˼b@קWצN0[薛^aiZ_IcU}H56$%dh(u?@; d{CC9tFn&|@.jy^'ᘦvB˂rb/=8&pw '[rrMOwo5u[{Si#Zzc4,{${I(g ONsQ- @6F'2<7ʫWjXy_uQx Ҙr[q63ƅ+,:i}UHYv }p.qAgpF) FO[¡7 x"\܎11=ӟ/Oha#Y<'~:-t÷;7  љcG Wb)1Zϣ^08mT '#}-\Ӻ_ݎw925&`{.C' @h2ĝ&u#6`del[='٩OZڧk@GQhv߮'۽ۯ}߿?|]>0bO*_z>HOh%wFŠ na/e+ E_3.3Aۻ"hl9Fv:MnG@^ضr&\wo.9\pi7yXP<)bdt0 4 N iΘk9}3vLu104_tCi@+2_65< kؓrylԵ,{Z%Naףը2 յnyѶ͘&H^IPm뙿Ie  6ltiL }AnBq0"pYIj0P8GfDK/Ʒkzڽk Mӈ8NQWfj4Yn{F戻4hgHv˚Z襚-ƊYfv {gVL8g*)6-t( .Mܻ5Lf ]ϻk|i@0HH_ x*2^[p{t^@6n# !8OalynZjdl] M94m ppii8dakk4M}xcۇI@QwݤzgQi.EL g{ߴv +@6&.3qTuU1 x(m"A* [6DLU$y Ʉۺ4WI7jaBXiD,}:,[$\؎rS/ i:)-t1mttE>8 !!O|y9,Wvʍސ<q\@;}]lg5z+[8 A,6FiL }1 `hb7p2i(%]of~?DR (Qݔ9KutҘhtAU]XSy>o3tۛW̬qnk[ڵW VNjk᪗^{x= ȌhpmGγ 3 e.|̾ڸqx t?^0¨T<-‰ZA^Q^?x X\Հ1dO@.RI`:tH N.x:C/MX7ʈhrq -3JgRccuMAB6$JWY,n\ ]ϻk]ti̺ܞFaz*OL+ fIכ+Ľ-5q{ Ib4dhXYIS8dmi@ ]߿^&`ڿ8ɩslK5j< &KNms:.u 4#$\tٴ8^t_JiL }D]63"GB>5P<3).J%:۲jB@ٻ.$yNJD}x&cGsjXyvQdD&Bڦ֙Ys 5qǴ$>3?Dj6 uwQEٍK!W0+jUXH-(G/&*o[TWy֛e18#J~-_,uZՕ8J1/Rm 6,`£mt÷;8w&Q8i^MM^iV2ۑ(zĽL@}q qo-JL0S30r˦02GdFh|K]+@8d?_ZFuS}2Ln<:]F/Q0ˠ.JQhW?1gLblN8BBE4hߚA{۷wjH\@l4V̒7& '#}-\bd8ӧ(< ̺ܞFtK_Zt{7&8\/ 818CF;E)E_ar Н^l@EF fcoJpY $;:z>{0D@넫^RV{l3̇"3?F[µzx\9\8@..`ZE}elC[<:%q;bu?kM>F@q~2Nik622߯nXjtqmInΗd2i(%]of5lMl-'p]G?)hO*AUr$:m<0<_h{}c\pv=8xIi@ 7-6e_hǺL@l/  dzڇ&iI櫾2ͫŇ5To 2._N&g]2_ꤥ1|]_+'!OXԻC94_gp H/aS <:ԨAlM_}*ww\+7,w8d^+]ޏx?޻h"-iھ͗> ۯa<%(KhM7|'<]yaB [hfuzaf`LֱMad1x@9_p22xa-YkS7+u@HYDךYG_y8pVgQ8t&VFm:@+߯ekq 7}ofQP` H9{pf`. tRw]#/N*_;z{+07%>. W专r[X@;uDvMV4->yr~^9u ju=7 MUB~IޝQ KBr˥gi׊rH93.ٴnL'3m4{*o;1jN+g;VB4 r0I1Mny8dW=e1r\=㚈rт,BZLiI_QXju=7ҍp&оrD_%QQ_ D@j. ,U Zh橗5 r}͌q ^bKɳ'U7D+ 0! ,Ǥ,Vp @>{qZyBSw*1L&˭c/qr ihϮ`Wc6O_h^E~rN/8?p4hEQԸKEslĮzӺ7EdMh̆<^:F@ .7$vi7d  @͌hp]W'dUd"\4BpgL3,fyꫫ]'h'Od}dKcb#8݄zKv 0F㴟Y_QoNE1̶,^,@! 2̺ܞFx]SVeXQ0Khi9FqQFAp=1L E.d;%UVUTߛ)Sb?kat]~|]Ҵz[S/WԷ?텥,AU_eTeF&](4*Edx:qeܚIgpZ!b]MtU57)؝؟GYPZ E)o1ˢo cuZ}&'@HxIXYiϮ oBFy/,X``D/@g_h^EY>ݎD9194aUbT<#ui1VTM](88leT7eN}NRЉ.&lqIqPTưʺ |-:iEajgյ =zc^]ٚSԺCh 9IKcf; ' \+ZO1.\u=ãkIU]BB<7ԙkg:YRAOFznj' ,O5 8 xPRyH4h{G< ^l@ufe8H7t5MqE<j)XrOٸkg"9xkӯSq3]Oy޽#* YL+ fIכفt]?tDel7 Uhtu^#]C4f3+0kpYmf }j׵ZMQ^ -DOo+~.Il7zC} U*N#"ә/gq\Vޢ lG.kzaf`LֱMad8) 24ʳ.ON sa4"'\;eZFuS3 qb" \xoo;A+'ksjNvmCE ڧS7h6zqfs3P/n[tQ l(i9%dBGl~\9\X\Q9h#AjUYh! XWI lG;bs@ eFh|ko3j@gEh8VAWjNjXqQ΂:- .JEQMDEhE턮xziqh9 N&{<>(11SH5 g@ e>[ RL0 O! awZUQ-:<-dzѢϴ6"MNGu&Q0WTV} T<-‰pF\}j]$_Ny鯽Ko߾7#\/ ϳWdSs W̬qnN/@CdѤKZכ2_t_ U@6iijCԝiˉ9'JH9^F!*M(rN0[薛5 R2Џ/> t4za<tvBD}k$ZO1.\~}VV#gr5x8ޒ_Fh,ȖIcE,z3;ؿ(\m00rB od^l7Ym{ǮgqTH֩&a[=  qޅD<\sqdjSEyTyZmY+5NuT2-ʴ(KjSy љ۩ m$!g!_^gFh|KxzO;Jǡa] jL < iKy ${Ay@Bd${Ǟ>6]ĉ"u^ftmaiD}@N:Y,]k>L+\'@+ wl$4&(>dkm=}J .cO344-ƊYfv z]tnfgcvW4 hU֙Ys jD k ?sO?hN _({*^^,MtIgV'{GQv?iQy4e]z=}&QQi[/qg!$\Ԃ.| + 8b^E.> CV<<x:i6th 8ϧM\i[cix+/8@GSKh?@W囿hNm ͟xǯKl4V̒7[&;Z*MgL7-la&mf W,72 „@t@)Y^͛ة4uPw&~_߻ m sٮܕAL]4 NQ"ӼSgaHƱYbpYd%D,[q63ƅ+lџx6 &j\aWughh貞6)fX^n@ 7ل(w(fO6=x0$݈nv$!64p prq \7ifFh|Kxьx?h~;W4xh.>&$gFZ&*(Zwƒ'(`#N26}dN OWjQ0zQqrbDMzjQݔ9q;E iQvn7yX 1@4Eyg!:siw뾦æoEt:B76I]7 +:9Ķkx {Gl3c\5B'=@::@ݽ͠ ە֙Ys 4{_TMSwe !uܴ~Fq0EaB@YDgnxa:c'>AvF]Y15# َ\@4P:moM bd '#}-<ĝk !8F}%Uqj,oD=}J .a=wNj#I0}wC}h|ɏ'겉J@ ( Q FǤ,Vp p|9jvgzaf`LֱMadZO1.\ᙖv}.#-,: q7W0iϕ_DFyJ[ubM6j\LG/ V2L.(B<?1!4&\NcQva%Fq9UЭtX|8j:&qcf? <ϡRFuSڽbH_@יv <*CvI:Βp̽Y2Z \;Mo3뭧߿o ʖIcE,z3;ib[.al~r-r)7!'xJdS~ŧfflcT%:(*n[nzvp>\ϓ,16IkNQh*3 Fjw ) @ 2{f 8 ȥ&mߏi7\'fѬfUhPy^gFh|Kx8id@11qE } '#}-<]IF/@sq!(4!$2 „@r J%Nf8n$ X'{u0 8ϳ ׻w방ZO1.\6egl;%,:͛( Ytu`i;+G-t4ֆp@$\^\ XK:) ;$@.1(ufDK/Ʒg8Jn>Qg 'L#p '#}-i#/LQݟ~&",tkk<2i(%]of3=MxΘg<)^zfIzr}IGKGup!$>uk9>fƸpg4qOI:8O捌piƖ=1FڛY4ֻK+˻QnpqeT7%ucp̥4q! .-nN ֳlmekx(4bi@vVjv#>BeZpNjmaڄŶ/'  h9x޾k&@ eFh|Kxd6hq2H֙-xZ8$#~<]ehϽn ]wfahG?WҘ@r*rWQ4,<**N4R /4 /⢜)aO?<@֙Ys i_}xhO/=0HH_ݽwꍷ)J˖IcE,z3;x2ԟ;p\h Gedtn,^d,=0_cN-V{`=;z;ڮoo;#3L< 8}yq@^s-^XոldSN> t{Vƛp TQe5b<OotKƉ=8W%ՀL/@'O4uNJx :~3J`\Bzk"pY("+UD.YAB}3@EaB Zgf]fnύt#\[wPTHvȕ4h"lr/=" zj$">?7"- ׽#-ٞ<l(ڙ-xZ8o~@pZ-tz:5 ۍZE&42G⛢ڇ ˖IcE,z3;hbk9>fƸp ڻnMr <|4醣ej"Ɏ̞l"tVjv#J/KelaVnBqQFA@25 8K'E|-tMI- '8"gw5AN {G }86On[SwyMĴ-h 'Dd%8\/eH_@.aq-Sa>vz6տeEBM^`Γ B8y^ufe8H73z^"@Ҍ-{b7xH M+7qC <Ǥ,Vp ̗8V+oQАlG}Vfj4Yn{F戓j@7}LTpRW0i p̮=(A^-)90HH_ K74K-|EJ4ق 6Za6aIrElY vS7yH _iYF$-sQ5t5mdVh,sSrC.">Ѥۙ: >^rj 8K_3.3AmNNn^@!H0.(`.88 *" FQ1t rSxli+:[&@xyNmbyMg<7,:Ͱֽ`93ݪufDK/Ʒ'f)6:7]63 R2»}%7ȥ6)^aaօZehp# \dLxϦkZN*Q F<.- jṢ`8=b/`VOן{=|hhWFuS|7C&@v6F5$ \BcOvW̬qngco~g4mow!d@fݫ7@1$ڨ3[,[z59QG,̓:RWEY/ 25a98I& id;\;ُ/  gt=Mw֥i:;a tô:I5Cb!Gvk9>fƸp?$}% >T>@kh :"^Es!$q ApQզG8N]%^dueS#:32s{nَvMs< }a4?p'[@.ZQ;< tCLC<R(jm?qk۫F4* NQ.7D,zV,|eT5EU=0{ M"]l"Xf^v6kYCo#p}1h9~YuUZO1.\a#RXpE>Weyb;΍(8ˀ\x]u7g'E (dW !yrsz8~SZ_  0=ף # Ng% [g5kw^=ugs#n+,V^.D fz#vLBr?7Pݾez *b[\JW޶LfOhkC- Ke=-p E)N0C+VvـdaiD}Rxsՙ·Uͨ)gznGVϚ__N_X'uhf᭪96n3՗t/p.zI3GlĽk!M}Tz?k֧~vBю8(E#EQI  B.,oӾrC .+Vil굿Zgf]fnύtC@8 Ѳ?^vM..>\gJcUPM پ*GK){ڇT|hN, zH;Nnl:I`Ab38|٫gZnӵ^N(-M\eof \\gXZ>*Q pNF9'&z٨kYJqϵYƙ7/H ְ4Og@>vڧO/ ʌhlOL׌֙·Uͨ)gDžg4gQߡ)LiVv4vr71FEB @W̬qng(Z/'N&7ƔE@o~ۯ{ׯC pk,C/Q~ gQao[&xr$,[q63ƅ+<&"9ISPF]p&qΌhGw5.v: R2²P G^WV벉>WvC~%ur3wfI+8 ;i0-3 ӳa#u2 kؓrylԵ,{Z%8en/̛qnEr ZcJϱ46|̷6$ӧ"p|I_@2̺ܞFxV@H!$LêvfTTp m!u`5UX@p\Vo{ˍcuda>8 B5(ԽvkV4t#:3רհ-Y-hln^E\ш),:͛syhקc(-cz2,ye<6!Cl4V̒7ap禮 +K/kݞs ?smD.>{jbڥvJ~]yFy- '#}-<ЮUfƸpɤx+:[&YaD FQ;iYuӼ 8ˀrܻ{*&Ҙr/`(ʯ78dn GբՁI_a=әQId;,| ώ;Z=];#i TgXr_H&Mvʽl^R paw~&F9ܻ4W̬qnv5E5ʖ[h^nTyB@2&\a 61g">d8zgZ([&}0HH_ յ_NiȶS228j.@۷ͷ?tr깆s2FHP-K-M^j=VbQ_55ҳ鹦iNyJM8*8:Rˠ^LKE|x(n.SW_'O+@!:9?4MMl-'\KZ:#+٬ѻFhrZFED ڇ0 {F}^hw\8sٙQ/(^|hr# '#}KWm ޤ VUM@Y(>A);Zh;7F8.4 ٽf (feBi#|@ eiƇ. ={<a8iO?h1#yK[}<"pz̲ɲ_6e/qE@l4V̒7a:"QB<(#ߟ/8opt-yXubkq=ӷ;5?ڸ뾓K{Zt>7!R\aP a?&e ӈX@ F,[$@  *1L&˭c/֙Ys sIliL qJs4oo$5oy6@׿>Io 6ާg=@+oշ8RM u^L7y1K&A\~(ja:y,fộXBc γSԪꔩ5BҴ:iڇedy3mƪ`W w5`_ s8 YM@SS٨6:\V_Wi#iV (ETuшC8y:ZVN ']dZ1JDԟ0M TOʌhևOaS<_ps^XՍSH~.H& !䊦UuhFgπds:2 gwspH|.uF<h6ϻkfL;EQbM'=VVo$ѽ3J@IBӴrC.4(v37+ܷxG@ l4V̒7y=ך^ OGTucZv'Nv$&Ed/tM  ;@ Z6ׇ0^ruA PPF(w:@Z\@_Ko\ :0>J<]+[;u"$>'x>횷@ƶ<"E+UږrE*!g]A N.܀|mm^Mƙ!GNG~ 8!!.6ANurv}=t6^ԚLVQݰ bywos㚰rjaś?͏_3hRu]VEw>m>1\[q63ƅ_S @ QY M>y:ZVN8gҘH_/&jՄ4!-Q83u&ڙNc{rLH\֓'Z_Ic#~mZ[{J* ٻwf7-e-SKpQݟh'kUs] nv$dAo\eNUN&Gp/bOC6*KmKuW }vUlbr=u(ev#%!gɌh=SgruMcv tz @dQI6.>Qi48w8*6t٣ae&M-CL}|KvP}5zok2{aU] @ܯ*}[YԄ\:@2w&<r+N'_w|paID:je-ҩdk&,r*׋̧.^acAZ8ih{CiLtYFp4q/[ׄUjz5`\- YW# >uk9>fƸpob@|k^3MMdFh|K WV4e7O{l4V̒7[rz4!wztp:CYXya7͌GD}H6.TTzFH^h+^"UIjJ;qz"/ŦG.k@ L# XQh[}NWV 6?}8~~_b ))synh?HF5? zGl3c\ulMtglvyE\ػwldq:X`@>&ﺆ^'vM@ rbOFMQײi;VfתZgf]fnύt#z{srftzI}eϴ?OpQyϻ0 <7zC} %~Lb g̗8V+oQhꎀ\oMv:838 tL @7uOαSeWԸEEzz(Oj|љDkS'?KӔ 3*p,UtJ7&@6W\891E vg8dDL+ fIכفp=,rگ (ұ9S3 YM] B*e *8q&k'}O#g)FNcnr f-6e ̺ܞF]/p UUl(iL}ĕK-hJ ̽ 2ܐ-tu&ҧ,Gɓ~_'Eꭼk_7~~g.ŪŤbڈ{@6VUTDԙD5Sr\s- Mq-t@*2.1YLF7 L'N3JlM].j%p¢6ݵ@63y>o3tۛ8T\zD+ F>@dˤ`tFpijM6h8V}P:̬b; BC2=Pde'ieiLquwW̬qn>\{Ozh%t_]3}ȁ(pk9>fƸpEp6_h0 vB x;&@;Z}5h5NSX!NX9uv8yxizw R04F"3?F[gFHru1r~0Wo퇯4g ! :LeXiD,}:,[.E9^|ma4"?7)TP@k}\)7A$?MHXYi0YM9HE(879սl4V̒7Z= <>(^}{k1"թnc}֌C@}-4mG`FwmY(B*(y2"=U*V8 'Ԭ{NӺ?aն׭a:[yLɼv,Ž]*@'O8d?&NvNw+3?F[`$ Y.pTCRӱ'OOs,"ZΝ8wgӪjoo^O;vtv\KN1y>M3@?h>a=~&0\_4 $HLEt;<0\Vpq''Pk{MW-׻TєZm6q^$˸Ynf%tIQg\J<=uQqtiH)1jr2T{$F3ICer B4 ?Ƨ&m-'Y6ӂ4=c3+ eZNs4-Ti m8G'vm[[uD.@11K?U;u:PgXvr] Sr ZhxYvYv^vjVk5|ujkX5euێ1odHv ɝdW 'ʌag`*QM߶s;,Vqt2'=+3zCjnj6e8['tnz>:[&@,WC/dh{,O; < !y^2G 8 *Zꮫ9wg#*7w״&YjLG_ULo*Z䮞ΣQ2*_trkU ^C -:ۯt1ߢW$ ԟdž ֡ZJ3Y ڣ@dcZhwjQk_´0 O! )Tà#~Lb ̗8V+oQppa;BβJL0S30r˦024egH6::'g>[7x(y_h^EN,(y)n4v6%/ ֻ' |to6=BM 1z0fS؞rtQ!zg}ƚ̓fds=h'Gd4265M@A}>*]rKcI>H/./ }h˪L O :DPD2" =k z쎬ˆrӦjAԾݾ" JoIfr) `p@ (Hm pfdXuПCs;#=!bp09G @ȇč? }9a7st pS:h*M @0j+h!ĺ$yzv\?I6Rx[gx(M%J\'j4`a=]Wnz+ |q{(rjqc#g:觟yFӈ5|.֙Q9qndv?7vZMGzb:'rbMF&rl5]&'e8epnOvC#53smޠGpcOY]kT]<MxM7zhR 2KKM_~˷PЬH@ls~m嶡i3,Vq8mkm g+⢌0`Id@+`Zh2:o QM%̊JHt^h=_,^ t Ampb=#XWϯc8~r Z벌JLS|EN0>ݿ NX7ZI9pfq!T_($ *1H@&ֶ3[>IJ xd) QQU9 =ݩ^nj¦hȚ.(73{kz(.,4s6~a[zYPky\|[SN"p{|(Y33Gv:M _6#d0>ѿ':N{  %Mb ϛY/W+wQ(8Ubh>Mm5ugQ㦻/Mٳ,~ASZq8>[t+@Wɯa4"'XJιIގyH7,isKGY?D0ڨ AV %bidΌωt#{(TFU]7ToB㕿xk㍿-r)+ "E|cȖ>[J`R?wx2MK!iyҒ:ܮuHVh8Ҩj~sb ,>tsUTƚOK"@AOFZ\U-/_6` vϧ`_=EHg tY< , {ִmmqȞkP,!)$YG*ċg_UufTexNڢ d ;8̈n8ln- -벌JHoOKFrauEVN OXv BZ:'hEȚ6` d1>9j@?Hy48Q$9@Ubh>Mm5ug|xc)@QU9`=6H@K<u{VN" BeHw=z+@;<E`;sUTƚ0 t{|rr6s53sm京V,%4%1ςm㩺Lm@K&yzZgr&.}o#2@KP?D {NFI7vHK6-i+gάx ƙtR?6ALUr"pڠ:8hZe>tA9 mM&Ly~6ԯ64q*8b@?LY/Tm|M@#k0d^̗ \ d,o!^X\) t2ijL-Z{N@=&(%;w}N-ǣdzjSz2т 62<hΟt|&]="0=15g&&@#+t9slnf^Wq @, @-ncK:v$ ܝl38e$% T$7iVNN蠻^OoB3J\g1ENdeT@O Z-6kڌY3+=ޥd'bs5m[l3}\8ie`גlY\+螪#6hǍ@'V{@^Uną{Rw@<ZjtaCE{)tPv;^j-+7LdT6>@ecZ(Oh|_3*3s Ȧi+ה^,(`#_g߿b'tcc_ye{vӏa8aToN(m^J4t|qpⅻyQ*D4(d8b^E.gMRQ0KTwf9 }cR98/ 2pn #5}4[jBl9ӣMw_z훲S@mM&LSSFU]|@3:_ZZOK(bd@!Ī: L1qH ԟ칞"u3/ƫ80Qo(jp$":nTU={N)@=yB @+4UՔ#c@;C2 }YLR]Z1T2 YӞ*袋ge"sl5]NXyG_g~ N._p{ =s@48_l <ˉ55jtL-fT':Yi&Zzp(tOIQCw2y>|Ǝo#kMk/b v?K|͗yboҔWg*Lmz5luR  zye{/~ogִmmqs}KI(<G(W^o_}ӷ?V@ZmhZ U\5{7Ea"ɔo,7{#}Z A@~0F-4atg:32s<'ҍ욪"qnziL{㷀ٻHaWi^GLDof2 E2ίkj^ ='#”G@K6@KtC'MhS(@Ubh>Mm5ug|zLUO0k( QpPbF45Uus#k0D. 88.#e>K;4m[7bZӜ6js{pS~7l4mM&L"?Qz8gÒޭxL7}oVAzԏsM{_Q`7[S5Z t?K>^ťٺqe;t|qLg%t!8Ubh>Mm5ug9usk2R|v@Cƹ:n@4p}ĵz*bM/v;[O#?mj3 :\ڋraka_y7h=4Us7]$k~g؎s=-Jtx]X"ą9@4 Cয়ufTexN3 E>, *%t@4@w'jMӅ=  H] v6<+ B6 {벌RBݎ/۴%'ntד'x}wV 'zxjnu6KlΓ']] 6JMcBZ?+)aꪢ(]*SL^vItk bEeDt<4FiuE7 '#mpрh Ov /P.PD>W6Ɵ_ɶrh6t4^åJH9>@y" 9,eGQpfidy0>ӏL}܏N^n@<' 0*$z)ʏ2/,ڹ=.`:ʍ'/(&,AU^^Fq&\ũe@t*~wo~܊⺮/| Rtχs\tWaF0t1Y##T2Ӟ2 ~ y/2rb4]pԏ2ۈE+Com⭧MՑ65Z\ :*7XћWX[[wj |p龘cX^Sݿ:j.|/ZziM0]KߨEHOվ?ѐ䫻ki_ᄆOeOzp?xvo&W{:G\%Ne$s5))mӆϥ8 pIh(6Gn|)! *L$mR`ϛY/W+wQ(Z%VӤVSzfYf՝Y\'"`_h^EN,pVw4A@v_|u+1/[7iXuFV8]]e?.07o i^M: iU(-*JhiL K8Xykڶ6fpw{Bh̥8.#βO4FQx|g2~u{DWmE~/~#=#BXa={s~EHxCgyiQ =߿￿9)&n@Z^)=3a@MU$^" :TY ڹU0@? L7}o}'yGg+%◻$4~)58sviQ@!˕VkZ~2^F⽫)ZgFUfAٟ@stHdumFOյt4 ~ X1dC3! ±puƉUgXmR3ŅWM@twy_-&>=Wյpf|H~蠻ߖQ*pIP{ëL g ODXuRms*@,MGAqݗ^nu\Kǃs1Hq0]F|@6G[k7DLt=KuG;%R sga4/BEZGQeLs?84{|ay3g}k4ܠQ~4_;"^ p;cZ`O  S4{ħpUM-%XTx/O͵t^q STF3{Ė, t@<ĝ ȇBAYf՝YTO^y]C_Me#u5m[l3}\8v\yg UmR`8h?ofq\EHw*1H@&ֶ3[>n6ucɯa4"'"XU 6z;`@< qZy4J=jrz@^UnETBZ=В|14F EQ^Dk+ Mka!$5ܟxf{CǬj6&﯒Sӎzelpd g"|@,Όωt#{[] 0HɰBi Fk"'1FyPd嚰bAOFZnEGaYr P=bՏXO-s@ʙxS? Uj/L? 3Bsx:\ڋraka_y7:A뮥M]$k空冦%3뗦"NW[.D;o m~tC(&fMAx@+.7γ]~@?uRymmf֬ԣžtjg0-K./R벌YB#ge64wS!=I~xVkSNvC `N,H HcbZOI?,/ :~lhvw] 1ښM>.!~_<3xɆYS(A@7Sņ "822g. wKb+5ImF,Qݙ]tXvyc<l3f -=6pEdeM_'!(Ubh>Mm5ug|!il>*(7 2X&F9];A꧶a{E= i;>'@/% ד'[-ג G@;[Ӷ6Dž#;(ŀ88.#Z9=ۚrC9ڃk $ xrtGsyɁZ@44ۀpbQW̨8H73 "~6݂C ;LgIGC3VM? r4I)$?7@ ._@n4IJ*p^闓(!a@⃫ZG×"NW["X!犑GIK5//i-g^QM6̚GlhiL Q\GqYhbmajqQl6}pՒAwf1kF`/|7K)\QUM! =%$  #Mb ϛY/W+wQ(ҝJ 0R#ЧI.̖:32s<'ҍ\>zZY:Z(:UZr <ԝ,I+R}tվ^f;V@cp׫ aD?ӘH|14Fr$DugV ki(Bʨ˜[TG1@4yb,EhʆriaНHG j_3*3s Țj?ik1=VITqOfQ$$! ˦]_y_eT}ͫՏ?9kk;?yn9Ί|@4yU~U2Jqݗ^~GUXϞ|5m[l3}\8?OP8m(@=yB .74j77q΋8Ӣ$=B3^+,d7q!+7=z 7~"u|LsƥHdݵ2@_8/|Yek9&EO=h'RWb P ֐1 g2_3*3s w$UENc4-2ʵt0LEa tQ]:B#[j9'$E9 S33:fTS}5cCA q߄E; \8̼R7ۆ`bt{<[O:}2)%]=AD;8 Y<hJwi!H6A3 ԟ53)-xemH!@;ڼߍʸI'lsۚM>.Y;U婺phJ]za(rR".rM^˜T@49].Jo^~{$DugV 8`>&3 /@}_QR=q>1 XZ(Oh|9ӣMw_z}~Kf ~^2Wo|Ao~myyXoa%6ά_h&rLZ1)@qK8$Hwʜd8݁7Yexb?RUz/x77D4lU~1"o&<Tޔg%!XGaZaFOfk[M]-AOFz!>hikڶ6fpy(7RUuHb_&4W˯oʖIYf՝Y~Gq0H=<[; MbAwԎ >}4YtoRM}=\ug,2=jt׾XT{&^̗ \ d,h@әdͩ @Zga6UQ'frUmi<2_butҌ- ׶ǷkG{hzD+2/hENJntU:N #쏄"T(@QU9<e:UGk}:& ta$cZ'=w+ճg+7= g="~r1Hq0]F༞tA97q PR83N1zD ԟRյ=UPbnp (Xq0]FiCpV3{*-H"u5,0U0lXY4@0J ]כBݑa-JC՟X6Mp8ZEi,=lT;bsX @@(Y@,|1l__V |^7\U@(2W@\k5f'E Y8Ie:-P|EX2=jt׾){4IJ$'6@LvJ@?+)8gIqUZCǝӅ%+=@gYbZ/ |14Fr$DugV ki(.z=O.jkqT/++ʉcQCw# /^ut3'Xر_dL~-vt@ 3a1 'k K<i/p^d*^{>ۆ5ΰXU!)s♙ ^>ڻMxM7zȄ^D [ 62;gv2K>|Ia5Օ랤0KC[/qgƸhvU~1"?!]}./YCq |_&ql$zV5#Bhޏ8ͣQ㦻/MtE@o?|o?}Bz/~CdI٘.=&&td0袇7tUIqtִmmqd_6o$W/(&ҼNekc]eŪ J[`䀿ZgFUfA{ϗ)m10Mu)ZN~@%: }ӓ4xXZFbe#tQOw32 „@V䇓 V$=$onPm9t:-#iYA7ZJ^o?#1K]dECGr7V pS4Ɖ1.%TVOWK>|/=ӣMw_zW'Q<~" cf՝Y~)X B<WiS1MErU?zB^-]^2Ҙ@ npi@"Ͷ(QBx 8pn2 &YvOp 1+hE*.sjE^b yiVmkm GTOU@}(VhVW4UOx4 Se%f~%pnzI32hPd4,Fdm4AV`QIzx 2Ջ(Gv GxtGYA :>,mL}mi(V@'8̓tC @+D+< Q檙e#>R=KB0„@VIY4"՟78^VP;iZaFOfk[M]-\Nk2_ߛ5W,:ލ}>0 @ q^Ι8,WDe  ~TL?4& =(<n 5 Ea;X < mCgXq t@*s♙ ^>̍S?wx2Mx iyҒ:ܮu?_ ^Då/vڹ&X~/~#=#>=Yf՝Yz:sdu=U Ӏh,@;jU9f?Rnz-uS k@Gz&\jӒ &kiĿ'st*} ]L- @ T`)K;vr7?|7mM&=?5VbzI0h算ƒ|pf)AbHaWi^G6qcfen4}zn:32s<'ҍzvٿAڐO@Ӕ߲g8@ODZeDt#uܪ,&(%;}s9_Ƹ_188BfrFKmqtJ%gTMS8Z vx[0Q㦻/{2S)Q\GqYhbm&pfl{iVvRܿ18^Y|/ؐW%t+@~rjNjWuR l,7_pb=#u \mCgXq y}<Wϯ z}A͍>2 „@VdƷ`)q2Kmkt\~]^܆AOFZ4Rϩ"E^yK pn7iVN'&fzԸK}svXXI@ǵ'ON.ԕߺ:32s<'~OVb@^e󺣇CW&Ia3 :wNs-B7cD{0>@7?OͰ Mch#F+ %! i &@WP퓑z"r8ZB3k돽.pVdXdX~*Qu# ,k+ Mkah.sx8IK95g&l8+J7`k g:ll>Ӎ Jz$wH61P̘/}MFzAlM&LGܠlITnz^\Q&DK>., }9/uPčM׮;MXo3=jt׾߂t$'N&ϟK{-Ƒ],r)+d\Ch*/h̉Ԭ$Z8?BSMD ԟzRpfahO]Oٟpf.&(ۆ.ݿ@{rt^8P ]A]s{MI7iIo4ͣRͧi5(*٣8[Όωt/x;+Su}2>r;g[ ϥ5N }9 ^ @Pq0]F7=@wpmMs+5rH"x-׈̱ko8\ &hKBZQb3h9. \㱱tx{ q4ʴ ȥ?<xD:32s<'~lȇW= yDʚ6` y_B]t! =I! .[8.n8 ?B :t5 pfeTenXBuA ;Uw We -cjKp@ Y37J~ &t|A)t]w֙Q9qnrNM#h%%$ S3=jt׾)(SvzR;[O#?mjb8c:\ڋraka_y73>KahGjrӣ]:vM*y|Qw@8N @1?U9oeWqE-(QALmkm Gg_ ԟn_cؖ5pj$#~^ZQlԁn?~ϧK|p5ݬ(*-mA#@[w=v5i2LQ=F~RBkR$W?MŪFf4f>#YwO+ 0! mR`8tOxZf1#X #5}4[jBl9kڌY3+؟quT1 }'@~w @,ڻO:}]gy& ^fzȮHBVzZsUnƒ|14F@22`QZVn8bWCHxܟxf{CǬj6&s,tRyy06(I5~_Ϥ>q~l ę (dq]5m[l3}\8MU1F(;ʑ\&zP=TiMb;( yQ_5K-?/M\]<& ]O?i*M׋GBZMyj q~XeW2nO7"LWt+@3W ZziL$9횾/}MtGVFj4iԅARf7@ezԸK}sl( x 8@s #-SG h*gnM,VQ&2螫W|^̗ \ d,o!65Яjʱt@4|j*~^4PqR2JtQNNhz< pfYf՝Y¥aR?ό2na gW& /ÇrӓffJ=Z D;Zs#AZuYFy_)џԷMGH+qǴ:b0xuaNxtsuV _jP :GnR|J SFYuޗ w)A>=22'=UYG@B$h8vW8\aZzw/ǯs:) |Q㦻/Tש"?Zz̓2RzZgi(M`bXI #5}4[jB"ijDU3'ޝ)Ab4]hxmxVm$*'( y;n,3]&pٳۚ"b*r?6ALU8Q*|Le, ԰Vr=<;!@|l񏚲??fe_((H]Cb-VFrVG5v?+`#_g߿vz~+|MB?Wr<"*I>0 iR'r hGa_- |qt:aL`w(>rWQ*-r9 R2ֲ9DSI$)xVFj4iԅִmmqȦQFD;x*5冨bQU9qt@3Қt @!8/Όωt#ۆ1@ K,Ua]cᾔTp^O:_/ɚ6` dG7v.m(}OSmM^=b%/:filugb6ؼq"tQ?LgIGC3VDR XG7ͦ"}O z0hfe_(Vnid4Ԇ$էDn#hG~8K}0;b}IKepf_@DKM3aHψ idtҁYZ>wbiڡ>-Xye%"vktt44hEDg@yfp FMOJcB%_r8ZB3kSC]3/5z0EPQ;FQUepp}$u{"U@,mR`8tOxZB!XwkZaFOfk[M]-gzԸK}S6MM>|:@n6e6zP p _nיִқ|+_Wx߲MhO~y@_~;|@;L7y=/{ql⥛2w+wd-ʑJ׻=.[1˨*E0`]l[5eUNjSZp++((Nh$gMRQ0KTwfYpҺ44Ͱykڶ6fpdM}$_C[/qgƸ46t;*xw?ikuZTnpv@1;@s tVFbgU3|sbo?|o?}#zAo^| yF{osQ]f-QT0RS]tr}x2c1 Z麱b48@ Όωt/Z n訔 t|q5m[l3}\8"1ĺ=F,4WM?_7q΋8ӢDk.WZ YjxnBV@4h=t|qfY|XQ?JO5MR!s )W0HɰBÁ 18V5UM ̇<(GrM{/:NچHeTeN|+FO>38\v|g]`A?i}Vf@mw@K:OoQut0P鸣V>rQzx$c xJ{s6@'ǰ`1,:_ *=nWaL)hd .@W<gu{\MeUT*:XIfcMYo qAG!=3BZ9=ak3B=U~l ę ($lA*|5h' ԰Vr=<;f <襵a+{\鏼5|,y u = XQ[rde4e|w_]K~o~m?WQBzaӟX6Mp8>髐@)7=)%`N t_N󊣒`y+Ms4!@%Q?Y%VӤVSzf,m6tчGYHeTeN`+8bs>WLe@H:USmC./?c}&&F9];,Gakڶ6fpd0wˬIj3 fά@4R~XeK@8bsP4A/n*. Us{xjU9FA%`_ʻ"Iۍpwz%E"G*WDx._J/h:\p:?ZC݊4'ó*F<#:4PqR2@g79voˑZf5/zB(&fMA8ފgm_WziL,Q\GqYhbmj&WY:/sJx{̉ VLM*tO$@+aP$Mb 8rr"@Ubh>Mm5ugûm]&Ng7v8o'l,o10՟tüόQe?פ'' :UZGϣW\Ịs&0Fβ䎯eGLzϟKy-T|4U:M((2Z&*{{RUn (#_3*3s Țf ›>GE.`8hZe>tA9ȀOVn8bW# rܟxf{CǬj6&+7[0Ƶ=T'n:)ŴP 땫^IIxR.|ε0I˯߼~L7}oʮǽpi)ne5ImF,QݙȚYMO0HɰB38yh6vr 3w&yzZ~(_5K-?/M\ Ҙbc@t:ٱ?@?JixOmqhw*1H@&ֶ3[><{:t@}d* yd:zUUt5eI?rؕl; ^_^KۮV[A? Z4M6hVe{I蠫WWC-Wnz'uo} [ pU% +WS0HH[V\  S[rJ\>Z86k=Ǥ"@$8ͣ5m[l3}\8RD@o?|o?}Bz/~Cd{:W5MZ(}E#Ʈm+a3HwTIgV'n"4d]ti(V@t@,YϛY/W+wQHS\S*ϔ@;M`8Z{?P8gW맟h wXOYD J:jVW:LL/xFӂ HށGaM/e+ :H>'ֶas}AO ԟiyf돦iݦ=@:8y x 8|5z8zRБ 4,`G<t}o0@? ֭ZgFUfAt$̳|U6(z5e H"XS@; xd&;zw2@ɷ5nkߔ5ݷV~vkڶ6fpdWA_#@,Y]T]wZ3|x꩹Y $!:n_r<冲 i,ǃmWUXCgAwT0m͍te _(gF=/ x:"=.MFZ>ê.fwid冸@E^yHvH`Zh@,:% '#m-kjOa'ۭid‘]ާj`܈Z=oɴk\WkͱkUQv2 `5nkߔ5*E$UЊ%*7gG+<'dPso}e1y>ы㫗o_螟|ǿW4+n~tדkhb*|,cc$dXE!!y&]=EÔtp {eVę;/\Ora'H{m$DugV {5ge%_p! =O! )ܽ tOTaB{IY4f] lX%EN\{`sϲ<N7MVFj4iԅAÿ4@,;oz=UGS ZѼJX@30Zwߓ:)@7-yxSo- Ua"+^oU%%d|a+ZgFUfA R ĿKHeTeν3"_8ͣ|Z. %@4uW͵jk؄g@ 5.@wWs?֕ hTO|Pbgqhˏ(0HH[ˎ+2) SInpC4 Z<E5羷'=aP$Mb /,(s#X #5}4[jBl9ӣMw_zH[>|r>[lijF*-r"Ö6tLtӆC6y@kYYpRrd){V\@xiIj3 fά`?Qoz~TǪT[-^Ol=*Ft?u q&* t@:X8hZe>tA9h3ƮMMƱ? ZH'g*hۃ2"?H6 R2{G?hKB%j>l@r,DoGxiSuMMdG` ^̗ \ d,o!:=yufTexNY< 9E֞k8Z-i!SH [ WD vU~1"N3M vy$ ~qVOԙc+*h珄"׋#7q΋8Ӣ$XLF[GylVb\č:r7^o駟q{r0:[]k|:/ &?6It*1H@&ֶ3g̵l)-eMRQ0KTwferCX{~Npʑ?0?7 qc_ho@ԯ64q*bq33:fTS}5Yٽ3gnX͉Aޗ1ſn8ۃ0M=4+ ~ uT@ZسV(kf(N硻uy'XaP a&e ӈX@,(t'C+ilm = 5Oc.t>鱛~7M~y9>t{S2pfdXEq@kMm\Upm-+,zRKE\F46b:r; ZUu3*7*ziX(I2-ʴ|:ٳ\j(A% pk{jO=,֦/4OW{BZIcbp^# E>((җ jSנ:bZȚ6` dʵtT@| '#mOZ|F}b"u #@^SCm2?keW. y~h1-1m6gVup -@K2 n෺ 8.#B s;o: 7pf=u-E9k9Znz=Gc7N9'WGIVזT]Zv\ 6y4qLLYznQ6Áf8?~_f;_L_n2axHoKM{z"VI:erth`YR:KI%Xb-C?G~8\ }D(*0HH[L\e?ؚM>.IshVܞ v{\k^F*6?FaQ/ Y= H4/J=V6³9H<Ԟ+{:YM#gzԸK}s_ҔkbZT6.Olj-0 3Bspݳ]E !nGH|puy:@4-rUr?2}]WI ;-kڌY3+-Q~]t`P3{8Yz*Iq:,ERR thЏN *5cpwߓ(E?iiCQM60ZiEZ'm&oM&L/z޿8wy(;ɐeѤ_^JiFI14eM$蠓&罛a/ϬY?֣Mw_zڬ:>I!׳a寚m,<;& /v9gA]@wG5|SCduOյ+7:lSCcp[D'=aP$Mb ԟ78^VP;iZaFOfk[M]G&Gg;h"5t"5sW0Wi :n o갤[ph677sU Qp:5TwYˌW *bc ݱ ʍt_qhq"_M? r_RU:֋/qӓrZv4 t*~wo֙Q9qnmSOEHbzz!\^ƒ|ɦHݥ~˰L՗/g밇P_Swpn\,mR`8 Sſ&ÙZSk|B>`B Zќxbqx?kXfcK{lSg.&.ur.`4Ks-'O}\_lM_O !W̨8H7?` }5 VAeTe~ӓje6ecWfvtb5 =<Ԟ+{:YM#/uat/(\^*7M6䋓Yqf^8q#\Rid}U?{&MO8 &gzԸK}S4{`/,El]Ea _ ])̕8Æ$j)@{#@9#c,oGvp,3J2=jt׾_;SO$O~acX8Ԯ].P@z < IA3-<`G*)j5A]Hjoh̎HqoGώ/ga '9'I֋ēMkp }4@ %u"hyx7-F@G6Ij3 fά`B2I蜣lSe+ >sǃ8LMDφC:ۍY,xN;MtC:d( R2@|>RO8a=Vnȸqq&g䏆(`Q0 J1yJ0 F9fy&E%F&ף` њK__!<@-?D'3(J!/3 $(_W[Z5z(j+L k Ozempic to Zepbound – Medical health insurance grapples with weight reduction medication price – Insurance Info News
Home Insurance Ozempic to Zepbound – Medical health insurance grapples with weight reduction medication price

Ozempic to Zepbound – Medical health insurance grapples with weight reduction medication price

0
Ozempic to Zepbound – Medical health insurance grapples with weight reduction medication price

[ad_1]



Ozempic to Zepbound – Medical health insurance grapples with weight reduction medication price | Insurance coverage Enterprise America















Eli Lilly and Novo Nordisk medication might trim down weight problems, however ROI questions linger

Ozempic to Zepbound – Health insurance grapples with weight loss drugs cost


Life & Well being

By

The Ozempic weight reduction recognition explosion has raised a dilemma for medical health insurance firms, authorities businesses, and different payer organizations, as they determine how equitable it is going to be to satiate demand for canopy for brand spanking new weight reduction medication like Wegovy and Zepbound and dampen the weight problems disaster with out working themselves ragged.

Amid Ozempic and different new diabetes and weight reduction medication’ booming recognition, healthcare payers – together with insurance coverage carriers – stay unsure of the return on funding (ROI) of recent weight reduction medication.

Whereas well being insurers have began to supply cowl for brand spanking new weight reduction medication, insurance coverage and healthcare professionals are usually trying to what was described by an actuarial skilled as a cautious strategy and it’s believed that extra analysis on potential fiscal and social advantages of widespread cowl for medication like Wegovy and Zepbound is required.

What’s seen as a prohibitive pricing given the scope of the weight problems epidemic might make it untenable for a lot of medical health insurance firms, different payers, and plan sponsors to proceed to supply widespread protection for the medication outdoors of essentially the most excessive instances and it’ll take time to grasp what any return on funding (ROI) may seem like even with the advantage of chopping down on obesity-related prices, based on Greg Warren, associate and consulting actuary with Axene Well being Companions and a fellow on the Society of Actuaries.

“Plan sponsors are considering, do I have to cowl it, ought to I cowl it, would it not assist keep away from hospital prices downstream if we had much less weight problems?” Warren instructed Insurance coverage Enterprise, acknowledging that the reply to the ultimate query might properly be a sure.

Nonetheless, he caveated: “However [they also need to know] what the return on funding is.”

From Ozempic to Zepbound: New weight reduction medicines touted for promising ends in tackling weight problems

“New-generation” anti-obesity drugs like Wegovy and Zepbound, which include the identical lively ingredient as diabetes medicines Ozempic (semaglutide) and Mounjaro (tirzepatide) respectively, have led sufferers to realize weight lack of 15% to greater than 20% in scientific trials, the New England Journal of Drugs has reported.

The marketplace for the brand new weight reduction drugs is there and enterprise is booming, with the medication having been touted by some as an answer to America’s weight problems emergency and a technique to reduce down on care prices.

How massive is America’s weight problems disaster?

America has been going through an weight problems disaster:

  • US grownup weight problems prevalence has been reported as 42% by the Facilities for Illness Management and Prevention
  • The price of the weight problems epidemic within the US is huge, at practically $173 billion in 2019, based on the CDC.
  • Adults with weight problems on common see medical prices that had been $1,861 increased than for individuals of a wholesome weight, the CDC discovered

Extra analysis wanted on ROI of recent weight reduction medication, insurance coverage and healthcare consultants say

Whereas there was pleasure across the weight reduction medication, the prognosis from some corners has not been solely optimistic.

If 80% of People with weight problems began to take Ozempic at its present price, “it might bankrupt the well being care system,” Dr Richard Kahn, former chief scientific and medical officer on the American Diabetes Affiliation, has instructed the New York Instances.

The Society of Actuaries has commissioned a analysis venture in partnership with Axene to raised perceive the overall price of care affect and ROI of recent GLP-1 medication, Warren instructed Insurance coverage Enterprise.

How a lot do Mounjaro, Ozempic, Wegovy, and Zepbound price?

Mounjaro, Ozempic, Wegovy, and Zepbound all have totally different record costs, with final price to the affected person influenced by a number of elements:

What’s the distinction between Ozempic and Wegovy?

Ozempic and Wegovy are manufacturers manufactured by Danish pharmaceutical enterprise Novo Nordisk:

  • Ozempic was FDA accredited as a type-2 diabetes remedy in 2017, whereas Wegovy was FDA accredited for weight reduction remedy in 2021 when it grew to become the primary drug accredited for persistent weight administration in adults with weight problems since 2014
  • Each Ozempic and Wegovy include lively ingredient semaglitude, however at totally different doses
  • Each Ozempic and Wegovy are administered by injection.

What’s the distinction between Mounjaro and Zepbound?

Mounjaro and Zepbound are manufacturers manufactured by US pharma large Eli Lilly:

  • Mounjaro was FDA-approved as a type-2 diabetes remedy in 2022, with weight problems and weight reduction remedy Zepbound having obtained FDA approval in late 2023
  • Each Mounjaro and Zepbound include lively ingredient tirzepatide
  • Each Mounjaro and Zepbound are administered by injection

Public curiosity in weight reduction medication, together with Ozempic, Wegovy, and Mounjaro has surged

Almost half of respondents to a 2023 KFF Well being monitoring ballot  mentioned they can be excited by taking a protected and efficient weight reduction drug, although simply 23% mentioned they’d have an interest if it was administered by way of a routine injection, as is the case for FDA accredited Wegovy and Zepbound.

Seven in 10 adults surveyed by KFF reported having heard not less than “a bit” about new weight reduction medication, which KFF mentioned included Ozempic, Wegovy, and Mounjaro.

The ’TikTok impact’ – social media and movie star gossip spurs Ozempic curiosity

The explosive extent of the recognition of medication corresponding to Mounjaro, Ozempic, Wegovy, and Zepbound has partly been pushed by a viral social media spike.

“Inside actuarial circles, pharmacy circles, pharmacists, scientific pharmacists, managed care circles, there’s even dialogue now about, ‘what is the TikTok impact, and the way will we quantify that?’” Warren mentioned.

In 2022, off-label use of blockbuster drug Ozempic spawned a #MyOzempicJourney TikTok development, Selection reported. The #Ozempic hashtag has been considered a whole bunch of thousands and thousands of instances, based on a New York Instances report.

Showbiz gossip has fueled additional curiosity, with some stars – reportedly together with Khloe Kardashian – having clapped again at hypothesis they’d used Ozempic or different GLP-1 medication to reduce weight.

“After all, not all individuals eligible are going to get [the drugs] – and could not and possibly should not, in order that brings up that query: what sort of inflammatory projections or illustrations are varied people placing on the market [and] how does that have an effect on individuals’s impressions?” Warren mentioned.

“Lilly Stands Towards the Use of its Medicines for Beauty Weight Loss: Mounjaro and Zepbound are indicated for the remedy of significant illnesses; they don’t seem to be accredited for – and shouldn’t be used for – beauty weight reduction,” Eli Lilly mentioned in a January 4 open letter.

Mounjaro, Ozempic, Mygovy, and Zepbound – seeing double, the insurance coverage price query

As insurers and different stakeholders weigh up the ROI and insurance coverage implications of recent FDA accredited weight reduction medication like Mygovy and Zepbound amid sturdy demand, they could additionally discover their needs in battle with these of pharmaceutical producers.

The multi-use factor of the medication imply that totally different manufacturers are FDA-approved for various functions, however the weight reduction medication totally different costs to these accredited for diabetes remedy. Eli Lilly’s Mounjaro and Zepbound are the identical strengths, which isn’t the case for Novo Nordisk’s Ozempic and Wegovy.

“It is the identical drug and has a unique worth based mostly on what it’s prescribed for, which is sort of new,” Warren mentioned. “The payers, plan sponsors, employers, well being plans, even authorities payers like Medicaid entities must be considering, ‘how will we get this for our weight reduction sufferers on the cheaper price of the 2? How will we get all of them on the cheaper price of the 2?’

“And naturally, the pharma producers are considering, ‘how do I get the upper worth for as many as doable?’ – and that is to not vilify them, per se, they’re attempting to make extra earnings they’ll reinvest into extra cures and extra therapies for society.”

New diabetes and weight reduction medication are usually not with out controversy

And whereas the medication have proved hotly fashionable, they haven’t been solely with out controversy.

Morgan & Morgan attorneys have claimed they’re investigating 10,000 claims over the medication. Eli Lilly and Novo Nordisk have labelled allegations “with out advantage”, Reuters reported.

What are GLP-1 medication?

Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs which have boomed in recognition as a consequence of their potential to assist with weight reduction.

  • GLP-1 receptor agonists mimic the GLP-1 hormone, which is launched within the gastrointestinal tract, based on the FDA.
  • Present FDA accredited makes use of of GLP-1 receptor agonists embrace for weight reduction, blood sugar discount, and stroke and coronary heart assault danger discount in adults with diabetes type-2
  • Semaglutide (the lively ingredient in Ozempic, Rybelsus, and Wegovy) is a GLP-1 receptor agonist
  • Tirzepatide (the lively ingredient in Mounjaro and Zepbound) is a twin GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor agonist
  • The primary GLP-1 receptor agonist diabetes remedy, exenatide, was FDA accredited in 2005.

What’s semaglutide?

Semaglutide is the lively ingredient in Ozempic and Wegovy:

  • Semaglutide is the non-brand identify for diabetes therapies injection Ozempic and pill-based Rybelsus, in addition to weight reduction drug Wegovy.
  • Semaglutide is a GLP-1 receptor agonist, which mimics the GLP-1 hormone launched within the gastrointestinal tract
  • Danish firm Novo Nordisk holds the patent for semaglutide

What’s tirzepatide?

Tirzepatide is the lively ingredient in Mounjaro and Zepbound:

  • Tirzepatide is the non-brand identify for diabetes remedy injection Mounjaro and weight reduction drug Zepbound
  • Tirzepatide is a GLP-1 and GIP receptor agonist
  • Tirepatide is present in Eli Lilly medication.

Weight-reduction plan and train versus new weight reduction medication – consultants at loggerheads

There are additionally competing views round whether or not weight loss plan and train, somewhat than medication, is a greater and more healthy repair for the weight problems disaster.

Nonetheless, producers and health consultants have clashed over adherence charges to each weight reduction drug and train regimes.

Actuaries like Warren are hoping for extra analysis and collaboration to construct an goal view on one of the best plan of action to assist deal with weight problems.

Insurance coverage suppliers more likely to stay cautious on Ozempic-like weight reduction therapies

Within the meantime, with medication like Mounjaro, Ozempic, Wegovy, and Zepbound persevering with to be extremely wanted together with off-label, Warren predicted that payers and plan suppliers will proceed to require people recognized as most in have to endure sequential assessments to safe cowl, beginning with weight loss plan and train monitored below medical supervision.

“If that fails, despite applicable effort, then you possibly can transfer on to one of many lesser price weight problems medication,” Warren mentioned.  “In case you attempt that after which it fails to work with all the fitting effort concerned, then you possibly can transfer on to having the brand new drug — that is how most individuals are serious about it.”

What’s your tackle the rise of weight reduction medication like Wegovy and Zepbound on the again of Ozempic’s recognition? What would be the insurance coverage affect? Share a remark under.

Associated Tales




[ad_2]

LEAVE A REPLY

Please enter your comment!
Please enter your name here